复合乳酸菌在溃疡性结肠炎治疗中的应用价值

Application of Lactobacillion Compound in the Treatment of Ulcerative Colitis

为探讨复合乳酸菌在溃疡忭结肠炎（UC）治疗中的应用价值，本研究采用随机对照方法。将30例轻中度活动期UC患者分为两组．各15例，一组予复合乳酸菌胶囊（聚克，联合奥沙拉嗪治疗（A组）．一组誓纯予奥沙拉嗪治疗（B组）。聚克的用法为每次0．66g（2粒）口服，每天3次；奥沙拉嗪的用法为每次1g口眼，每天4次。两组均治疗1周。结果显示，治疗后两组临床症状总积分、疾病活动指数、肠镜指数积分均显著降低，P〈0．05；其中A组降低更明显，P〈0．05。结果表明，复合乳酸菌剂加奥沙拉嗪治疗轻中度活动期UC安全、疗效肯定，优于单用炎沙拉嗪，值得临床推广应用。

The objective of this study was to investigate the applicable value of lactobacillion compound for treating ulcerative colitis. Thirty patients with ulcerative colitis（mild and moderate in active phase） were randomized into two groups. Patients in the study group（ n = 15 ） received capsule of lactobacillin compound（CLC） plus olsalazine, while patients in the control group received olsalazine only. CLC was used 0.66g/time（2 capsules）, tid.and olsalazine was given 1.0g/time, four times a day; treatment lasted for 4 weeks. As results,the general scores in clinical symptoms, disease active index and scores of enteroscopic exam of the patients in the two groups were all reduced（ P 〈0.05） ,and that in the study group were reduced more markedly（ P 〈0.05）. It is concluded that application of lactobacillion compound plus olsalazine can ensure a definite therapeutic result in the treatment of ulcerative colitis（ mild and moderate in active phase） ,better than olsalazine only,worth to cbinically generalizati on and usage.